ArticleBiochemistry and biophysics reports2025
CEBPB as a prognostic biomarker and its association with immune cells in clear cell renal cell carcinoma.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell transcriptomic analysis identifies decreasedTranslational cancer research · 2026Article
- USP7-stabilized CEBPB promotes HpSCC progression by upregulating IL6 to activate the JAK2/STAT3 signaling.Molecular and cellular biochemistry · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy with a poor prognosis. This study examines the expression, prognostic significance, and immune association of CCAAT/enhancer-binding protein beta (CEBPB) in ccRCC. RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) Project were analyzed using the STAR workflow and R software. Immunohistochemistry (IHC) validated CEBPB expression in ccRCC tissues. Functional enrichment analyses (Gene Ontology and Kyoto Encyclopedia of Genes and Genomes) and a protein-protein interaction (PPI) network (STRING and Cytoscape) were used to explore CEBPB-related pathways. Single-sample gene set enrichment analysis (ssGSEA) revealed significant correlations between CEBPB expression and the infiltration of 24 immune cell types. CEBPB was linked to immune-related pathways, including humoral immune response, leukocyte migration, and cytokine signaling. PPI analysis identified strong interactions with STAT3/EP300, highlighting its role in immune regulation. Cox regression analysis showed that high CEBPB expression is associated with poorer overall survival, supporting its potential as a prognostic biomarker. In conclusion, CEBPB plays a key role in shaping the immune microenvironment of ccRCC and may serve as a novel prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.